Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen | Zendy

Baocun Li | Zendy; Yang Wang | Zendy; Fang Shen | Zendy; Min Wu | Zendy; Yaming Li | Zendy; Zhong Fang | Zendy; Jianyu Ye | Zendy; Li Wang | Zendy; Lu Gao | Zendy; Zhenghong Yuan | Zendy; Jieliang Chen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen

Author(s) -

Baocun Li,

Yang Wang,

Fang Shen,

Min Wu,

Yaming Li,

Zhong Fang,

Jianyu Ye,

Li Wang,

Lu Gao,

Zhenghong Yuan,

Jieliang Chen

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00465-18

Subject(s) - repurposing , drug repositioning , pharmacology , retinoic acid , virology , drug , hepatitis b virus , virus , medicine , biology , chemistry , biochemistry , ecology , gene

Currently available therapies for chronic hepatitis B virus (HBV) infection can efficiently reduce viremia but induce hepatitis B surface antigen (HBsAg) loss in very few patients; also, these therapies do not greatly affect the viral covalently closed circular DNA (cccDNA). To discover new agents with complementary anti-HBV effects, we performed a drug repurposing screen of 1,018 Food and Drug Administration (FDA)-approved compounds using HBV-infected primary human hepatocytes (PHH).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research